Hints and tips:
...“It’s a Cinderella story,” said Stacey Schultz-Cherry, an infectious disease specialist at St Jude’s Children’s Research Hospital in Tennessee....
...While at St Jude, he established a vaccine study centre in the Eastern Highlands of Zimbabwe with Africa University....
...In April last year, Abbott announced a $25bn acquisition of St Jude Medical. Clinching both deals would see its debt soar from $9bn to $31bn, the FT has previously reported....
...There are plenty of others, including St Jude Medical (acquired by Abbott Laboratories in January of this year), which is currently battling lawsuits relating to vulnerabilities in its implantable cardiac...
...St Jude Medical has filed a suit against Muddy Waters, a hedge fund that said last month that the company’s cardiac pacemakers were vulnerable to cyber attacks, alleging that it intentionally made misleading...
...St Jude Medical has filed a lawsuit against a hedge fund that last month claimed its cardiac pacemakers were vulnerable to cyber attacks, alleging it concocted an “insidious scheme” to knock down the group...
...Now it is using a cyber security firm and a cardio electrophysiologist to allege that St Jude Medical makes pacemakers that can be hacked and should be recalled....
...St Jude Medical, a pacemaker manufacturer, was accused in August of having a security flaw in its devices in a report propagated by Muddy Waters....
...He said he would not implant the St Jude Medical pacemakers in patients until the problem was fixed....
...But in April it announced a $25bn acquisition of St Jude Medical. Clinching both deals would see its debt soar from $9bn to $31bn....
...Abbott’s acquisition of St Jude could spark a fresh wave of healthcare M&A, with a particular focus in the medical devices and technology focused medical equipment....
...Under the terms, Illinois-based Abbott will pay $46.75 in cash plus 0.8708 Abbott shares for each St Jude share, valuing the medical devices company at about $85 per share....
...The union of medical device makers Abbott Laboratories and St Jude Medical was rumoured last year. Sanofi felt good enough to make a $9bn hostile bid for biotech upstart Medivation....
...US pharmaceutical Abbott Laboratories also on Thursday announced a $25bn deal for St Jude Medical, while France’s Sanofi earlier today went public with the details of an unsolicited bid for San Francisco-based...
...The largest was Abbott’s $30bn agreed takeover of St Jude Medical in a cash-and-stock deal that would bring together two of the leading US manufacturers of heart-related medical devices....
...So we’ll also keep an eye on St Jude Medical’s defamation lawsuit in Minnesota against Muddy Waters and MedSec Holdings, after their report claiming its pacemaker devices were unsafe earlier this year....
...His dissertation was on the poem “V” by the Leeds poet Tony Harrison, set in a Leeds graveyard during the 1984 miners’ strike....
...Abbott Healthcare, which AbbVie was spun out of in 2013, said it would buy St Jude, a medical device group, for $25bn, while France’s Sanofi launched an unsolicited $9.3bn bid for San Francisco-based Medivation...
...Elsewhere, St Jude Medical, a maker of devices for the heart-care industry, surged by 25.5 per cent to $77.78 after Abbott Laboratories said it agreed to buy the group for $25bn....
...* This story has been updated to reflect the fact that Abbott has denied that it is preparing a bid for St Jude Medical...
...to come, says Natasha Merat, associate professor in transport studies at Leeds University in the UK....
...St Jude Medical shares fell 1.7 per cent to $41.21 after the stock’s rating was cut to “underperform” by RBC capital....
...Jude Medical Cardiac Rhythm Management Division (“St. Jude”). AorTech and its subsidiaries have served on St Jude a Rectification Notice, which asserts material breaches by St....
...St Jude Medical , Medtronic and Boston Scientific rose 3.9 per cent to $37.21, 4 per cent to $35.98 and 1.8 per cent to $5.60, respectively, but were still several percentage points lower than Friday’s...
...Rival St Jude Medical rose 3.2 per cent to $35.70 after it said it still expected to meet fourth-quarter and full-year guidance....
International Edition